Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study.

Abstract

HR 756 is a new cephalosporin derivative suitable for parenteral use. The compound possesses an unusally broad spectrum of antibacterial activity especially against gram-negative bacteria. Besides Escherichia coli, Salmonella, Klebsiella, indole-negative Proteae and other species also indol-positive Proteae, Serratia marcescens, Enterobacter and many Pseudomonas aeruginosa strains are inhibited by this compound. HR 756 is stable to most of the beta-lactamases produced by gram-negative organisms. Tests on different infection models also provided evidence of the high efficacy of HR 756 in vivo.

• Authors: R Heymès, A Lutz, E Schrinner
• Journal: Infection (Infection) Vol. 5 Issue 4 Pg. 259-60 ( 1977) ISSN: 0300-8126 [Print] Germany
• PMID: 413795 (Publication Type: Journal Article)

Chemical References

• Cephalosporins

Topics

• Animals
• Cephalosporins (pharmacology, therapeutic use)
• Dogs
• Enterobacteriaceae (drug effects)
• Klebsiella Infections (drug therapy)
• Mice
• Microbial Sensitivity Tests
• Pseudomonas aeruginosa (drug effects)
• Pyelonephritis (drug therapy)
• Rats
• Staphylococcal Infections (drug therapy)
• Streptococcal Infections (drug therapy)